Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15339MR)

This product GTTS-WQ15339MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15339MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7045MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ462MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ2064MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ8757MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ12666MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ4314MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ4335MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ9836MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JTX-2011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW